Keratoconus disease
Oct 21, 2025
FDA Approves Genentech’s GAZYVA for Lupus Nephritis; Glaukos’ EPIOXA Wins FDA Approval for Keratoconus Treatment; FDA Accepts Replimune’s RP1 BLA Resubmission for Advanced Melanoma; Cogent’s Bezuclastinib Earns FDA Breakthrough Therapy for SM-AHN; Amgen’s TEZSPIRE Gets FDA Nod for Chronic Rhinosinusitis with Nasal Polyps
FDA Approves Genentech’s GAZYVA for Lupus Nephritis Genentech, a member of the Roche Group, announced that the FDA has approved GAZYVA (obinutuzumab) for the treatment of adult patients with active lupus nephritis (LN) receiving standard therapy. The approval is supported by data from the Phase II NOBILITY and P...
Read More...
Sep 04, 2020
Keratoconus – Rare? Not really!
The Keratoconus market will be dominated by lenses, cross-linking procedures as well as IVMED-80, if approved in the coming decade. Keratoconus, away from the general perception of a rare disease, has come a long way. Thirty-four years back, in Minnesota, United States, this disease was claimed as rare, which ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
